Phillip M. Friden

LipimetiX Development LLC operates as a biopharmaceutical company. It develops drugs for the treatment of refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases by decreasing arterial cholesterol content and inflammation. The company is headquartered in Natick, MA.

eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA.

Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA.

Faraday Pharmaceuticals, Inc. develops small molecule drugs for the treatment of central nervous system disorders and cardiovascular diseases. The company was founded in 2001 and is headquartered in Seattle, WA.

Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million.

Transport Pharmaceuticals, Inc. engaged in the development of medical products for the treatment of multiple dermatological diseases. It developed iontophoretic technique to effect trans-dermal drug delivery for a number of dermatological conditions. The company was founded by Dennis I. Goldberg in 1999 and was headquartered in Framingham, MA.